Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
Xencor, Inc.
University Hospital, Clermont-Ferrand
University College Cork
Kaiser Permanente
Indiana University
University of Arizona
BioNTech SE
Indiana University
Jonsson Comprehensive Cancer Center
Loma Linda University
Swiss Cancer Institute
St. Olavs Hospital
University Medical Center Groningen
West China Hospital
UNC Lineberger Comprehensive Cancer Center
University of Arizona
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Western University, Canada
BioNTech SE
Columbia University
University of California, Irvine
University Health Network, Toronto
City of Hope Medical Center
Centre Leon Berard
University Health Network, Toronto
Seagen Inc.
Astellas Pharma Inc
Fudan University
University Medical Center Groningen
M.D. Anderson Cancer Center
University Health Network, Toronto
University Medical Center Groningen
Second Affiliated Hospital of Guangzhou Medical University
Royal Marsden NHS Foundation Trust
University Medical Center Groningen
Queen Mary University of London
National Cancer Institute (NCI)
Haukeland University Hospital
IRCCS San Raffaele
Dana-Farber Cancer Institute
Karabuk University
Eastern Cooperative Oncology Group
Endocyte
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Sun Yat-sen University
The Netherlands Cancer Institute
Ludwig Institute for Cancer Research
Agri Ibrahim Cecen University